{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T09:15:34Z","timestamp":1793610934686,"version":"4.5.0"},"reference-count":18,"publisher":"American Medical Association (AMA)","issue":"11","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Oncol"],"published-print":{"date-parts":[[2025,11,1]]},"abstract":"\n Importance<\/jats:title>\n \n Ribociclib, 600 mg showed substantial survival benefits in patients with hormone receptor\u2013positive (HR\n +<\/jats:sup>\n )\/\n ERRB2<\/jats:italic>\n \u2013negative (\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ; formerly\n HER2<\/jats:italic>\n ) advanced breast cancer (ABC) in the phase 3 MONALEESA trials but was associated with dose-dependent adverse events (AEs) that were manageable with dose reductions.\n <\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To investigate whether a 400-mg ribociclib starting dose could reduce the incidence of AEs while maintaining efficacy in ABC.<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n The AMALEE phase 2, multicenter, randomized, open-label, interventional noninferiority study was conducted between June 18, 2019, and December 8, 2020, and included pre- and postmenopausal women with newly diagnosed HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC. The study was conducted across 107 sites in 23 countries (across Europe and Australia, Latin America, North America, and Asia). The data were analyzed at the final data cutoff (August 30, 2024).\n <\/jats:p>\n <\/jats:sec>\n \n Interventions<\/jats:title>\n Randomization 1:1 to ribociclib, 400 mg + a nonsteroidal aromatase inhibitor or ribociclib, 600 mg + a nonsteroidal aromatase inhibitor (premenopausal patients also received goserelin).<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Overall response rate (ORR; primary end point); \u0394Fridericia-corrected QT interval (QTcF) from baseline to cycle 1 day 15, 2 hours postdose (\u0394QTcF; secondary end point); duration of response (DOR); time to response (TTR); progression-free survival (PFS); pharmacokinetics; and safety. Final analysis results are reported.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Baseline characteristics and prior anticancer therapy were balanced among the 376 patients (median [range] age, 58.0 [27-96] years). Median (range) follow-up from randomization was 53.5 (36.0-64.0) months (final data cutoff: August 30, 2024). The absolute ORR difference between ribociclib, 400 mg and ribociclib, 600 mg was \u22127.2% (ORR ratio, 0.87; 90% CI, 0.74-1.03). With ribociclib, 400 mg vs ribociclib, 600 mg, median PFS (26.9 vs 25.1 months) and DOR (26.5 vs 28.8 months) were similar; TTR was longer (13.1 vs 9.0 months). The maximal plasma concentration after dose and the 24-hour area under the curve (measured at the primary data cutoff) were 28.0% and 42.7% lower, respectively, with ribociclib, 400 mg than ribociclib, 600 mg. Ribociclib, 400 mg had a shorter \u0394QTcF (12.5 vs 19.7 milliseconds at cycle 1 day 15, 2 hours postdose), lower grade 3 or4 neutropenia rate (41.0% vs 58.5%), and fewer patients who required dose reduction due to AEs (29 patients [15.4%] vs 69 patients [36.9%]). Liver-related AEs, kidney toxic effects, interstitial lung disease or pneumonitis, and AE-prompted discontinuation rates were similar between arms.<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n \n The AMALEE randomized clinical trial did not demonstrate ORR noninferiority of ribociclib, 400 mg vs ribociclib, 600 mg, with comparable DOR and PFS between doses. Ribociclib, 400 mg had longer TTR, lower pharmacokinetic exposure, and lower rates of QTcF prolongation and neutropenia. The final results confirmed the standard ribociclib, 600 mg starting dose in HR\n +<\/jats:sup>\n \/\n ERBB2<\/jats:italic>\n \u2212<\/jats:sup>\n ABC while supporting dose reduction to manage dose-dependent AEs.\n <\/jats:p>\n <\/jats:sec>\n \n Trial Registration<\/jats:title>\n \n ClinicalTrials.gov Identifier:\n NCT03822468<\/jats:ext-link>\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamaoncol.2025.3687","type":"journal-article","created":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T15:31:20Z","timestamp":1758814280000},"page":"1356","source":"Crossref","is-referenced-by-count":10,"title":["600- vs 400-mg First-Line Ribociclib in Hormone Receptor\u2013Positive\/\n ERBB2<\/i>\n -Negative Advanced Breast Cancer"],"prefix":"10.1001","volume":"11","author":[{"given":"Fatima","family":"Cardoso","sequence":"first","affiliation":[{"name":"Breast Unit, Champalimaud Clinical Center\/Champalimaud Foundation and ABC Global Alliance, Lisbon, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Jacot","sequence":"additional","affiliation":[{"name":"Institut du Cancer de Montpellier Val d\u2019Aurelle, Montpellier University, INSERM U1194, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sherko","family":"Kuemmel","sequence":"additional","affiliation":[{"name":"Breast Unit, Kliniken Essen-Mitte, Essen, Germany and Department of Gynecology with Breast Unit, Charit\u00e9 Hospital Berlin, Berlin, Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[{"name":"Tata Memorial Centre, Homi Bhabha National Institute, Mumbai, India"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Cruz","sequence":"additional","affiliation":[{"name":"Nucleo Pesquisa da Rede Sao Camilo, Sao Paulo, Brazil"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rama","family":"Balaraman","sequence":"additional","affiliation":[{"name":"Florida Cancer Affiliates, Ocala"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Ferreira","sequence":"additional","affiliation":[{"name":"Instituto Portugu\u00eas Oncologia Porto, Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tytti","family":"Ahola","sequence":"additional","affiliation":[{"name":"HUS Comprehensive Cancer Center, Helsinki, Finland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yana","family":"Chapko","sequence":"additional","affiliation":[{"name":"Arkhangelsk Regional Clinical Oncology Dispensary, Arkhangelsk, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lyudmila","family":"Zhukova","sequence":"additional","affiliation":[{"name":"Loginov Moscow Clinical Scientific Center, Moscow, Russian Federation"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wendy","family":"Chiang","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Li","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Ji","sequence":"additional","affiliation":[{"name":"Novartis Pharmaceuticals Corporation, East Hanover, New Jersey"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadia","family":"Kaakiou","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalia","family":"Bolotova","sequence":"additional","affiliation":[{"name":"Novartis Pharma AG, Basel, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph A.","family":"Sparano","sequence":"additional","affiliation":[{"name":"Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, New York"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"key":"coi250057r1","doi-asserted-by":"publisher","DOI":"10.1016\/j.breast.2024.103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7).","volume":"76","author":"Cardoso","year":"2024","journal-title":"Breast"},{"issue":"18","key":"coi250057r2","doi-asserted-by":"publisher","first-page":"1738","DOI":"10.1056\/NEJMoa1609709","article-title":"Ribociclib as first-line therapy for HR-positive, advanced breast cancer.","volume":"375","author":"Hortobagyi","year":"2016","journal-title":"N Engl J Med"},{"issue":"24","key":"coi250057r3","doi-asserted-by":"publisher","first-page":"2465","DOI":"10.1200\/JCO.2018.78.9909","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor\u2013positive, human epidermal growth factor receptor 2\u2013negative advanced breast cancer: MONALEESA-3.","volume":"36","author":"Slamon","year":"2018","journal-title":"J Clin Oncol"},{"issue":"7","key":"coi250057r4","doi-asserted-by":"publisher","first-page":"904","DOI":"10.1016\/S1470-2045(18)30292-4","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial.","volume":"19","author":"Tripathy","year":"2018","journal-title":"Lancet Oncol"},{"issue":"7","key":"coi250057r5","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1093\/annonc\/mdy155","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer.","volume":"29","author":"Hortobagyi","year":"2018","journal-title":"Ann Oncol"},{"issue":"10","key":"coi250057r6","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1056\/NEJMoa2114663","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer.","volume":"386","author":"Hortobagyi","year":"2022","journal-title":"N Engl J Med"},{"issue":"6","key":"coi250057r7","doi-asserted-by":"publisher","first-page":"514","DOI":"10.1056\/NEJMoa1911149","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer.","volume":"382","author":"Slamon","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"coi250057r8","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1056\/NEJMoa1903765","article-title":"Overall survival with ribociclib plus endocrine therapy in breast cancer.","volume":"381","author":"Im","year":"2019","journal-title":"N Engl J Med"},{"issue":"1","key":"coi250057r9","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1186\/s13058-023-01701-9","article-title":"Updated overall survival from the MONALEESA-3 trial in postmenopausal women with HR+\/HER2- advanced breast cancer receiving first-line ribociclib plus fulvestrant.","volume":"25","author":"Neven","year":"2023","journal-title":"Breast Cancer Res"},{"issue":"8","key":"coi250057r10","doi-asserted-by":"publisher","first-page":"1054","DOI":"10.1002\/jcph.1856","article-title":"Ribociclib population pharmacokinetics and pharmacokinetic\/pharmacodynamic analysis of neutrophils in cancer patients.","volume":"61","author":"Lu","year":"2021","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"coi250057r11","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1002\/jcph.2310","article-title":"Quantitative assessment of ribociclib exposure-response relationship to justify dose regimen in patients with advanced breast cancer.","volume":"63","author":"Ji","year":"2023","journal-title":"J Clin Pharmacol"},{"issue":"12","key":"coi250057r13","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1056\/NEJMoa2305488","article-title":"Ribociclib plus endocrine therapy in early breast cancer.","volume":"390","author":"Slamon","year":"2024","journal-title":"N Engl J Med"},{"issue":"7","key":"coi250057r15","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1002\/cpdd.853","article-title":"Evaluation of absolute oral bioavailability and bioequivalence of ribociclib, a cyclin-dependent kinase 4\/6 inhibitor, in healthy subjects.","volume":"9","author":"Ji","year":"2020","journal-title":"Clin Pharmacol Drug Dev"},{"issue":"5","key":"coi250057r17","doi-asserted-by":"publisher","first-page":"679","DOI":"10.1038\/s41416-021-01415-9","article-title":"Safety and impact of dose reductions on efficacy in the randomised MONALEESA-2, -3 and -7 trials in hormone receptor-positive, HER2-negative advanced breast cancer.","volume":"125","author":"Burris","year":"2021","journal-title":"Br J Cancer"},{"issue":"2","key":"coi250057r18","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/s40262-023-01338-z","article-title":"Use of pharmacokinetic and pharmacodynamic data to develop the CDK4\/6 inhibitor ribociclib for patients with advanced breast cancer.","volume":"63","author":"Ji","year":"2024","journal-title":"Clin Pharmacokinet"},{"key":"coi250057r12","author":"Harbeck"},{"key":"coi250057r14","author":"Cardoso","year":"2022"},{"key":"coi250057r16","unstructured":"European Medicines Agency. ICH topic E 14: the clinical evaluation of QT\/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. Accessed February 1, 2025. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-e-14-clinical-evaluation-qtqts-interval-prolongation-and-proarrhythmic-potential-non-antiarrhythmic-drugs-step-5_en.pdf"}],"container-title":["JAMA Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/articlepdf\/2839159\/jamaoncology_cardoso_2025_oi_250057_1763138452.08651.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T16:02:44Z","timestamp":1763654564000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamaoncology\/fullarticle\/2839159"}},"subtitle":["The AMALEE Randomized Clinical Trial"],"short-title":[],"issued":{"date-parts":[[2025,11,1]]},"references-count":18,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamaoncol.2025.3687","relation":{},"ISSN":["2374-2437"],"issn-type":[{"value":"2374-2437","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11,1]]}}}